Interesting work from @chmoei.bsky.social et al! They observed that gut archaeal methanogens don't associate with MS onset or progression in a case-control cohort, but vary in treated patients vs. untreated which could reflect microbiome health during treatment.
🔗 https://journals.asm.org/doi/full/10.1128/spectrum.02183-24?af=R